EDSA News and Press, Edesa Biotech Inc. From 10/10/23

TORONTO, ON / ACCESSWIRE / October 10, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA) ("Edesa" or the "Company"), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today is announcing that it intends to effect a one-for-seven reverse share split of its com...

Company's host-directed therapeutic, EB05 (paridiprubart), demonstrated a statistically significant mortality reduction among critically ill patients with severe respiratory disease TORONTO, ON / ACCESSWIRE / September 28, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharma...

2023-08-09 17:35:56 ET Edesa Biotech press release ( NASDAQ: EDSA ): Q3 GAAP EPS of -$0.10 beats by $0.07 . At June 30, 2023, Edesa had cash and cash equivalents of $6.46 million and working capital of $5.39 million. For further details see: Edesa Biotech GAA...

TORONTO, ON / ACCESSWIRE / August 9, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three and nine months ended June 30, 2023 and provided an update on its business...

TORONTO, ON / ACCESSWIRE / July 26, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that the company will participate in a Fireside Chat and host one-on-one meetings at the Canaccord Genuity...

Positive Findings Support Potential Expanded Uses for Paridiprubart TORONTO, ON / ACCESSWIRE / June 28, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced positive findings from an in vitro st...

2023-06-27 08:46:21 ET Biopharmaceutical company Edesa Biotech ( NASDAQ: EDSA ) said on Tuesday that its board has appointed Stephen Lemieux CFO, effective July 15. Lemieux is a veteran of the healthcare and biopharmaceutical sectors, and has served as CFO of Titan M...

TORONTO, ON / ACCESSWIRE / June 27, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the company's board of directors has appointed Stephen Lemieux, CPA to the role of Chief Financial Of...

2023-05-11 17:30:50 ET Edesa Biotech press release ( NASDAQ: EDSA ): Q2 GAAP EPS of -$0.12 beats by $0.05 . At March 31, 2023, Edesa had cash and cash equivalents of $7.47 million and working capital of $6.56 million. Subsequent to the end of quarter, equity sales unde...

TORONTO, ON / ACCESSWIRE / May 11, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three and six months ended March 31, 2023 and provided an update on its business. ...